Newsletter | October 29, 2019

10.29.19 -- Best Practices In Partnering With A CRO


A flexible collaboration to help you address your viral vector manufacturing needs now, with an eye toward the future. Learn about viral vector solutions.

From The Editor

Hello Cell & Gene readers,


When it comes to partnering with a contract research organization (CRO), many pharmaceutical and biotech companies, particularly small ones, have no choice but to outsource. I caught up with Bob Paccasassi, VP of quality and compliance operations, and Mandy Clyde, VP of operations at BioRestorative Therapies for their insight on the best strategies for selecting and partnering with a CRO.


Rapid changes in the biopharma industry are making it increasingly difficult to launch new products successfully. In this article, we review the five key levers for biopharma launch success and explain how they inform the creation of a high-performing product launch framework.


Erin Harris, editor in chief
Follow me on Twitter

Industry Insights
Single-Use Systems For Storing And Shipping Frozen Drug Materials
Article | CPC

The logistics of decoupling drug substance manufacturing from final drug product formulation is now possible using integrated single-use freeze-thaw assemblies that incorporate reliable components.

Consistent Cord Blood Cryopreservation
Application Note | GE Healthcare Life Sciences

VIA Freeze controlled-rate freezers are compact electrical systems that do not require liquid nitrogen for freezing cells. Conduction-based cooling enables consistent cryopreservation of cells, including those in umbilical cord blood.

Custom-Designed Clinical Manufacturing Cleanrooms For Penn Medicine’s Cell And Gene Therapy Operations
Case Study | AES Clean Technology, Inc.

A GMP manufacturing suite was developed from its inception by AES, which included a custom-designed and constructed clinical manufacturing cleanroom core for producing PENN Medicine's cell and gene therapy candidates.


FDA/CMS Summit 2019 draws the highest leadership at the FDA and CMS and through an outstanding speaking faculty composed of 38 regulatory, policy, and industry leaders delivers the best available information on FDA and CMS priorities, policy changes, evidence-based practice, federal review processes on various areas of biopharma such as CDER, CBER, CDRH, and the most cutting-edge advances in healthcare and technology.

An Introduction To The XURI Cell Expansion System W25
GE Healthcare Life Sciences
Connect With Cell & Gene: